Upcoming Webinars

cancel
Showing results for 
Search instead for 
Did you mean: 

Upcoming Webinars

When evaluating drug-drug interaction (DDI) risk of an investigational drug, a battery of studies is needed to investigate victim/perpetrator potential. One of these comprises evaluation of the potential of a new therapy to inhibit drug-metabolizing enzymes, which can impact clearance of concomitantly administered drugs. The team at XenoTech has built a reputation of dedicating high-quality resources and specialists to conduct such studies with scientific rigor.    In this webinar, Jennifer Horkman, Study Director Team Supervisor in Metabolism Research at XenoTech, will address frequently asked questions from sponsors seeking inhibition studies and elaborate on some recommendations to achieve successful regulatory submission. Points of discussions will include an overview of enzyme inhibition studies and critical considerations in design, from determination of supporting data to conclusive interpretation.    The Q&A portion of this webinar will be led by Lois Haupt, Principal Scientist in Technical Advising at XenoTech. Both Jennifer and Lois have 20 years of DDI research experience at XenoTech and Lois’s 2015 paper on CYP inhibition is cited in the 2020 FDA final guidance, “In Vitro Drug Interaction Studies– Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions.”    Key Learning Objectives: Why is measuring CYP inhibition important? FDA guidance requirements CYP inhibition study design Standard study considerations CYP inhibition decision tree IC50 determinations Who Should Attend: Research scientists and drug development leadership aiming for successful IND / NDA submission, needing to meet regulatory requests and expectations, desiring to formulate a development plan that mitigates risks of late-stage failure, or simply wanting to better understand the ADME properties and potential DDI risks of their compound. Brought to you by:   Speakers: Jennifer Horkman Study Director, XenoTech Lois Haupt Principal Scientist, XenoTech Ann Thayer Contributing Editor, C&EN Media Group
%7Bb78086d6-f7a7-4c1d-9012-c755f4bba048%7D_drug-metabolizing-enzymes
Labels (2)
Optimizing olefin isomerization typically involves time-consuming testing of both intermediate and final product. The unavoidable delay between sampling and process changes using traditional chromatographic methods fails to eliminate the need for post-production adjustments and can even result in batch loss.    In this webinar, Tiffany Adkins, Quality Manager at Aurorium, will explain how fast, specific Raman spectroscopy improved her manufacturing quality and reduces product loss. She will discuss her phased implementation approach to Raman and lessons learned, the simplicity of quantitative method development and future use cases for the technique.    Elena Hagemann, Metrohm USA Spectroscopy Product Specialist, will give an overview of Raman spectroscopy and explain how the fundamentals of this technique make it well-suited for specialty chemicals and formulated products.    Key Learning Objectives: Discover how Raman spectroscopy gives quicker results than most other analytical technologies, leading to better response time to process variations Gain understanding on how Raman spectroscopy can be utilized to quantify the isomerization content in olefins via the variation in present double bonds Learn about overcoming implementation challenges in Raman Spectroscopy by showcasing different challenges, the approach to find solutions and the key learnings that will ease the implementation of Raman spectroscopy Who Should Attend: Those in the chemical industry, both specialty chemical and final product manufacturers looking to increase production quality and efficiency Production and QA managers of all industries seeking solutions to get actionable data faster Product development chemists seeking to design products for quality and manufacturability Researchers looking for Raman measurement solutions for a variety of materials Process development engineers and scientists looking for upstream/development solutions that can scale with production Brought to you by:   Speakers: Tiffany Adkins Quality Manager Aurorium Elena Hagemann Spectroscopy Product Specialist Metrohm USA Kelly McSweeney Contributing Editor C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
For many industry labs, scientific data has historically been generated to answer specific, immediate research questions and then archived to protect IP with little attention paid to the future value of reusing the data to answer similar questions. The resulting data often lack a consistent structure and quality. In addition, the highly manual workflows that produce this experimental data are complex, slow, and expensive. Altogether, this leads to most R&D labs today having surprisingly small datasets that are actually suitable for machine learning and AI.    Faced with this ‘small data’ situation, researchers and managers often feel that they may not yet benefit from pursuing data-driven approaches like Materials Informatics to new product development. They are not sure what can be done now to most effectively move forward. At Enthought, we have tackled many materials and chemicals product development challenges and have employed multiple techniques for getting the most value out of small data to meet innovation goals. In this webinar, we’ll present proven strategies and tips for how teams can make the most of what data they have and set a course towards continuous improvement through Materials Informatics.     Key Learning Objectives: How to develop a successful strategy for implementing digital R&D approaches across your organization in a conservative business environment.  How to start benefiting from data-driven product development methods even without a lot of data.  The critical role that chemical experts play in being successful with data-driven approaches. Several tips and tricks for building better ML models and AI recommendation systems with less data. Who Should Attend: R&D Managers  R&D Directors  Senior R&D Researchers    Brought to you by:   Speakers: Chris Farrow, Ph.D. Vice President of Materials Science Solutions, Enthought Michael Heiber, Ph.D. Materials Informatics Manager, Enthought Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7B9045dfc0-8891-45a9-89f4-ff4cd1982cfd%7D_20230410_Enthought_Webinar-Banner-01%5B6%5D
Labels (2)
Thursday, May 18, 2023
This webinar will guide you on the best practices, tools, and techniques needed to get the most reliable, verifiable insights into your optical components. Appropriate choice of technique and methodology is critical to getting the information you need to improve design, verify product performance, and accelerate manufacturing.     We will explore the subtleties of reflection and transmission measurements at normal incidence and at oblique angles, emphasizing high absorbance, optical density, linearity, and effects of incident beam collimation. We will discuss diffuse scattering measurements and automation/robotics to broaden quality assurance programs and speed up analysis.    The webinar is relevant to developers of optics, photonics, and electro-optical or semiconductor devices such as visual displays, laser-based range detection (LiDAR), optical communications systems and light-based scientific instrumentation. Improve your understanding of the link between your desired outcomes and the spectrophotometric approaches needed to achieve those insights.    Key Learning Objectives: The best spectrophotometric practices to extract deeper insights into the characteristics of optical samples.  How to overcome the limitations of traditional spectrophotometric tools and verify outcomes.  Accelerating QA/QC of optics in a production environment.  Who Should Attend: Commercial or Academic organizations in the fields of optics, photonics, electro-optical, or semiconductors Laboratory Managers  Scientist/Staff Scientists Lab Technician/Technologist Analyst Project Manager SME Directors, Core Lab/ Facility Managers  Under/Post Graduate Researchers Brought to you by:   Speakers: Travis Burt Global Product Manager – Cary UV-Vis-NIR Spectrophotometers, Agilent Technologies Catherine Dold Health & Environment Writer, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Library synthesis is the process of synthesizing a series of compounds and evaluating them for hits that have desirable therapeutic properties toward a given target. This approach allows project teams to undertake efficient and systematic screening of biological pathways or target classes, improving the success rate of drug discovery programs. Pharma companies are increasingly developing and applying innovative capabilities to make better molecules faster. Many enabling chemistries and technologies have been developed to improve the access to target molecules with expanded chemical diversity.    The development of high-throughput experimentation technology has made it possible to execute a large number of experiments in a short time frame, enabling the rapid identification of suitable reaction conditions, thereby expanding library accessible chemical space and allowing more diverse molecules to be made via parallel synthesis. With such higher-quality molecules, chemists can increase the success rate and reduce cycle time of hit finding and lead optimization. Moreover, new protocols can be used to guide the follow up of singleton compound synthesis, improving the efficiency of medicinal chemistry research. Attend this webinar to learn more about these recent advances in parallel library synthesis.    Key Learning Objectives: Review the concept and application of parallel medicinal chemistry (PMC) library synthesis Learn how PMC can provide more compounds with limited scaffolds, as a more focused approach to target molecules Understand new protocols to guide the follow up of singleton compound synthesis to improve efficiency  Who Should Attend: MedChem Project Managers and Directors  Medicinal Chemists  Outsourcing Managers Brought to you by:   Speakers: Dr. Yan Xu Executive Director, Head of Library Business, Research Chemistry Service, WuXi AppTec Ann Thayer Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Process development runs through the entire life cycle of new drug development and plays important roles in each stage. However, as the purpose of each development stage changes, the priority of the process development also changes accordingly. For the IND stage, the main purpose of process development is to scout the most efficient way within a limited timeline to produce the API, ensuring timely toxicology study and subsequent clinical trials. Therefore, rapid delivery of API is crucial for a timely IND submission.     In this webinar, we will discuss the importance of phase-appropriate process development and various frequent-encountered challenges in process development during the IND filing stage. These risks include scalability difficulties resulting from an inappropriate medicinal chemistry process; process safety issues; unanticipated risks of residual PGI/elemental impurities; API delivery delays caused by inappropriate specification settings; and scheduling challenges in delivering tox batches within restricted timeframes. With case studies, we will dive into these challenges in detail and share our experience in resolving them.     Key Learning Objectives: The importance of phase-appropriate process development for IND filing  Common obstacles and difficulties in process development  Who Should Attend: Early-Stage Drug Developers  R&D Scientists Brought to you by: Speakers: Renyun Guo, Ph.D. Senior Director, API Process Development, WuXi STA Ji Qi, Ph.D. Senior Principle Scientist, Discovery Process Chemistry Lead, MSD Ann Thayer Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Drug discovery chemists often ask two common questions: “What is the most efficient way to test my hypothesis?” and “How can I iterate on my ideas quickly?”    Digital chemistry offers a modern paradigm for answering these questions by enabling rapid in silico testing of design ideas using highly accurate digital assays of key properties, accessible across whole project teams. This shift from design strategies based largely on experimental trial and error towards a ‘predict-first’ approach to drug discovery allows teams to dramatically expand the pool of molecules that can be explored and results in a highly interactive and fully in silico design-make-test-analyze (DMTA) cycle. Chemists are empowered to test hypotheses through predictive modeling and iteratively improve designs prior to compound synthesis. Teams can confidently spend time and energy exploring new, unknown, and often more complex designs while sending only the top performing molecules for synthesis.    In this webinar, we will walk through the digital chemistry strategy used by Schrödinger’s Therapeutics Group, which has led to several successful clinical-stage drug candidates. We will demonstrate how this strategy is based in LiveDesign, Schrödinger’s cloud-native, collaborative enterprise informatics platform, which empowers teams to design, computationally assess, and prioritize new compounds together in real-time.     Key Learning Objectives: Predict properties: Understand how computationally-guided molecular design and a predict-first strategy can accelerate and improve your small molecule drug discovery process  Centralize technology: See how Schrödinger scientists used a digital chemistry platform to enhance crowdsourced ideation and team collaboration Overcome collaboration hurdles: Learn how a centralized platform for molecular design and discovery can increase project efficiency by securely and easily sharing data with internal and external CRO partners  Who Should Attend: Medicinal Chemists  Synthetic Chemists  Computational Chemists Digitization Managers  Research IT R&D Leadership  Brought to you by: Speakers: Eugene Hickey Senior Research Leader, Therapeutics Group, Schrödinger, Inc.   Alice Hooper Senior Scientist, Therapeutics Group, Schrödinger, Inc. Wade Miller Senior Scientist, Schrödinger, Inc. Olivia Lynes Strategic Deployment Manager, Schrödinger, Inc. Catherine Dold Health & Environment Writer, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Thursday, June 22, 2023
Chemical and materials science impacts 96% of manufactured goods and 100% of humanity. Advancements in this space will enable scientists to help solve many of society’s most pressing problems and unlock unprecedented growth. However, to date, technology has not been able to deliver the scale, speed and accuracy required to rapidly accelerate progress. That’s all about to change.   In this special session Dr. Nathan Baker, chemist and leader of Microsoft’s Azure Quantum partner development team, will explore how advancements in cloud technologies, artificial intelligence, high performance computing, and quantum computing are accelerating progress for scientists around the world. As part of this, Dr. Baker will also share breakthroughs in molecular simulation in the cloud that are enabling new applications for computational chemists and materials scientists, advances in quantum computing, and how you can get started using these methods today.     Key Learning Objectives: How progress can be made today by combining advanced cloud computing technologies to accelerate discovery in chemical and materials science. Real-world insights from industry leaders like Johnson Matthey that are already using Azure Quantum to accelerate quantum chemistry calculations. How researchers in chemical and materials fields can get started on their quantum journey today. Who Should Attend: Computational Chemists Computational Materials Scientists Digitization Managers Brought to you by: Speakers: Nathan Baker Head of Partnerships for Chemistry and Materials, Azure Quantum at Microsoft Catherine Dold Health & Environment Writer, C&EN Media Group
%7B3ba07f67-d610-4ac9-b6f0-3302a33c0de5%7D_230513_ACS_Banner_1200x600
Labels (2)
In this webinar we’ll see how implementing automation solutions can benefit analytical labs and empower life science researchers with the tools to significantly improve their experiments, obtaining superior data and more reliable outcomes. Join us to learn more about how automation and the connected lab have been utilized to improve analytical method development workflows of scientific researchers.    Method development is a critical, often time consuming, process for analytical laboratories. Imagine being able to create robust and precise analytical methods more quickly by streamlining the optimization process. Through laboratory automation, researchers can rapidly test and refine multiple method parameters simultaneously. Automated equipment performs the tedious and repetitive tasks, and thereby reduces potential errors and variability. Connected with regulatory compliant-ready software, technology transforms laborious manual procedures to error-free, robotic workflows with improved reproducibility and productivity in a fully traceable environment.    Key Learning Objectives: Learn how automation can add efficiency to your method development processes Discover the benefits of automating tedious, repetitive tasks Be introduced to an ecosystem of connected laboratory automation solutions Who Should Attend: Method Development Scientists  Researchers   Automation Engineers Laboratory Managers & Directors Lab Technicians and Technologists Project Managers Companies/Labs/Organizations Involved in Testing and Analysis    Brought to you by:   Speakers: Don Trinite Senior Principal Technical Support Specialist, Waters Corp. Meagan Callis Principal Product Marketing Manager, Waters Corp. Kelly McSweeney Contributing Editor, C&EN Media Group
%7B323be592-5155-4c37-a5e0-c104b701c761%7D_WatersBannerImage
Labels (2)
A thorough knowledge of size, porosity, and surface area is important in characterizing food powders. Furthermore, predicting the flow behavior of food powders is important to ensure no unexpected issues are encountered during handling in industrial processing.This webinar will focus on technologies that enable powder size, surface area, porosity, and flow evaluation (via powder rheology). A good understanding of these powder parameters, along with the flowability of the powders, paves the way towards optimizing process conditions to achieve a quality final product.     Effects of both internal influences like particle shape, size, size distribution, density, as well as external influences like humidity, temperature, and degree of consolidation, will be highlighted for end product usage and flow behavior of food products through several case studies.    Key Learning Objectives: How intrinsic material attributes affect a sample’s processability The impact of environmental conditions, such as temperature, humidity, and consolidation on final product attributes Essential tools and techniques for the characterization of food powders Who Should Attend: Anyone working in Food Research & Development, or Food Science  Food Manufacturers, Quality Control/Assurance Brought to you by:   Speakers: Dr. Brian Rodenhausen Particle and Materials Characterization Lead Scientist, Anton Paar Dr. Abhishek Shetty Advanced Technical Center Lead Scientist, Anton Paar Kelly McSweeney Contributing Editor, C&EN Media Group
%7B2f96df0f-3f7e-4c1f-a4a8-e6edeff1589c%7D_Food_Powders_Banner
Labels (2)
Labels (2)
Effective oil and condition monitoring enables proactive maintenance strategies and minimizes unexpected failures of machinery such as turbines. By closely monitoring the condition of lubricating oils, maintenance professionals can reduce downtime, extend equipment lifespan and identify potential issues before they escalate. Antioxidants are often added to mitigate these issues, which makes monitoring these chemicals critical for equipment performance.    Join Paul Swan, Technical Manager, APAC at ALS Tribology, and Larry Tucker, Director of Norms and Standards at Metrohm USA, as they discuss vital aspects of oil and condition monitoring and the importance of antioxidants in tribology. Gain valuable knowledge on ASTM methods and discover the latest insights into improvements being made in these areas.     Key Learning Objectives: Importance of antioxidants in lubricants and their impact on equipment performance How to use voltammetry as a tool to monitor remaining useful life on antioxidants in lubricating oils Importance of oil analysis in predictive maintenance strategies Understanding the significance of condition monitoring in preventing unexpected failures Insights into developments aimed at refining ASTM methods Who Should Attend: Anyone currently monitoring remaining useful life of antioxidants in lubricating oils Anyone using ASTM methods for oil and condition monitoring Laboratories, equipment manufacturers, oil and additive producers and electric utilities looking to monitor oil conditioning and antioxidant levels in use Brought to you by:  Speakers: Paul Swan Technical Manager APAC, Australian Laboratory Services Tribology Larry Tucker Director of Norms and Standards Metrohm USA Melissa O'Meara Forensic Science Consultant C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
  Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability.  In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies.  In this webinar, we will share our experiences and insights of the mechanistic aspects of preclinical pharmacology in the areas of neurodegenerative diseases, NASH, and metabolic disorders (involving PCSK9, in particular).  Additional discussion will focus on how such insights are used in testing new modalities such as oligonucleotides and AAV that target the CNS or the liver.    Key Learning Objectives: Review spontaneous Alzheimer-like dementia, diet-induced NASH and other metabolic diseases in small and large animals Dive into the clinical relevance of NASH models and insight into hepatic fibrosis  Learn how PCSK9 expression levels and/or activity are affected under metabolic induction See how these mechanistic insights can help in testing new modalities  Who Should Attend: Project Managers in Drug Discovery  Program Leaders and Directors of Drug Discovery  Scientists in Drug Discovery, including Medicinal Chemists, In Vivo Biologists in Neurodegenerative Diseases and NASH and other Metabolic Diseases, Pharmacologists, etc.  Scientists who are interested in new modality therapies Brought to you by:             Speakers:   Deming Xu, Ph.D. Chief Pharmacologist, Executive Director, Head of In Vivo Pharmacology, WuXi AppTec Discovery Biology       Kelly McSweeney Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Wednesday, September 13, 2023
RNA molecules are promising drug targets due to their genomic prevalence, disease involvement, and druggable complex structures. Successful examples include RNA-targeting small molecule drugs for spinal muscular atrophy (SMA), with on-going efforts in other RNA-related diseases.     Here, we present our toolbox for discovering RNA-targeting small molecules, with a focus on unique DNA-encoded libraries (DEL). Using DEL, we have identified several compounds against diverse RNA targets, including the human SMN2 (survival of motor neuron 2) mRNA. Rigorous validation using established assays such as SPR, ASMS, FID, and cellular splicing assays confirms the functionality of the DEL-selected compound in regulating SMN2 splicing. Additionally, SHAPE-MaP analysis provides insights into the compound’s potential mechanism of action.     Our findings demonstrate the feasibility of screening RNA-targeting small molecules using DEL. Furthermore, we highlight alternative screening methods to identify RNA-targeting compounds, along with valuable downstream biophysical and biochemical validation techniques.    Key Learning Objectives: Learn how SHAPE-MaP analysis is efficient for fast RNA structure and binding site verification Understand how specialized DEL, FBDD and ASMS are powerful tools to identify RNA-targeting small molecules Review how various orthogonal assays can be employed to validate RNA-targeting small molecules  Who Should Attend: Industry leaders, directors, and project managers focused on drug discovery Academic researchers involved in drug discovery projects Biotech/Pharma scientists focused on RNA-based therapeutics Scientists who are interested in new modality-based therapies Brought to you by:               Speakers:   Dr. Zhifeng Yu Director of Assay & Screen, WuXi AppTec       Dr. Ma Zhongyao Associate Director, Early Discovery, WuXi AppTec       Jeff Huber Contributing Editor, C&EN Media Group  
ACS Webinars Hub Placeholder Image.png
Labels (2)
CADD in an industrial setting requires high accuracy with maximum throughput to drive the drug discovery process. The SILCS technology, in conjunction with the CGenFF program, attains this at an unprecedented level through the use of pre-computed FragMaps that can be used throughout the drug discovery and optimization process. This includes the ability to iteratively improve the predictability of the FragMaps during the optimization process as well as extract atomic detail contributions to ligand binding that can facilitate interpretation of experimental data, offering an additional competitive advantage.    The inclusion of contributions from protein or RNA flexibility, desolvation contributions of the protein and RNA as well as the ligands and ligand-protein interactions in the precomputed SILCS FragMaps yields the combination of high accuracy and computational efficiency. This information content offers the ability to identify novel allosteric sites, perform virtual screening through both pharmacophore and SILCS docking approaches, rapidly estimate relative ligand binding affinities without requirement of an experimental structure of the lead compound. Beyond small molecule drug development the comprehensive nature of the SILCS FragMaps allows for analysis of protein-protein interactions that may be combined with docking of excipients, buffers and ions to the full protein surface to guide the formulation of protein-based biologics including monoclonal antibodies.    Key Learning Objectives: SILCS is based on pre-computation of an ensemble, termed FragMaps, offering a 1000-fold or more savings in time and resources over competing CADD technologies at a level of accuracy consistent with FEP. Pre-computed FragMaps can be utilized iteratively throughout all aspects of a medicinal chemistry campaign including the ability to iteratively improve the predictability of the FragMaps. SILCS FragMaps include contributions from protein flexibility and desolvation allowing for the identification of novel allosteric binding sites as well as taking into account local protein or RNA conformational changes to binding estimates. Who Should Attend: Computational chemists working in drug design and development Medicinal chemists interested in applying an accessible CADD technology during ligand design Formulation scientists working in protein-based biologics therapeutic development Brought to you by:               Speakers:   Alexander D. MacKerell Jr. Chief Scientific Officer, SilcsBio LLC       Olgun Guvench Managing Partner, SilcsBio LLC       Abhishek Kognole Applications Scientist, SilcsBio LLC       Oliver Tao Applications Scientist, SilcsBio LLC       Melissa O'Meara Forensic Science Consultant, C&EN Media Group        
ACS Webinars Hub Placeholder Image.png
Labels (2)
Thursday, September 21, 2023
Peptides, and in particular macrocyclic peptides, are well known for their ability to disrupt protein-protein interactions (PPIs).  However, it's challenging to screen for and discover novel macrocyclic peptides.  High throughput screening compound collections generally include few such molecules, and other techniques are limited to macrocycles comprised of naturally occurring (or similar) amino acids.    In this presentation we will discuss the use of DNA encoded libraries to discover peptide macrocycles that disrupt PPIs and provide a case study employing the oncoprotein murine double minute 2 (MDM2). We will also highlight the advantages of DEL compared to other methods, which includes the ability to use unnatural amino acids. This provides greater chemical diversity with smaller ring sizes and facilitates subsequent hit development as it pertains to beneficial PK properties.     Key Learning Objectives: Learn the potential advantages of using DEL for discovering cell-permeable cyclic peptides Learn the basics of how such DELs are designed and the current status of the field Learn how to follow up on DEL hits and some discussion of emerging techniques Get a sense of timelines and difficulties that exist when conducting such a screen Who Should Attend: Researchers interested in macrocyclic peptides, in particular cell permeable peptides Researchers struggling to find chemical matter capable of inhibiting PPIs Brought to you by: Speakers: Alex Satz Executive Director, Head of WuXi Biology DB Europe, WuXi AppTec Anthony Silvestri Head of Discovery Chemistry, Unnatural Products Catherine Dold Health & Environment Writer, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Water impacts battery materials at various levels, ranging from the molecular structure to overall performance. It can react with salts, causing corrosion and short circuiting and, ultimately, a reduction in battery life. Karl Fischer titration, known for its accuracy in measuring trace amounts of water, is an ideal method for monitoring water content in various battery components. This includes not only cathode and anode raw materials, but also electrolytes and separators used in the battery manufacturing process.    During this webinar, Dr. Roman Neufeld, Sr. Research Scientist from Honeywell, will discuss recommended coulometric KF reagents for battery electrolytes with and without reactive additives. Eduardo Simões, Product Specialist at Metrohm USA, will discuss how to analyze battery materials using Karl Fischer titration and provide an overview of other titration battery applications.    Key Learning Objectives: Learn how to analyze battery liquid samples for moisture and avoid side reactions with special KF reagents. Understand how the KF Oven technique works for solid materials and for liquid samples that cause side reactions with direct inject.  Learn about the main potentiometric titration applications for battery materials such as lithium salts, HF, and pure metals like Ni/Co/Mn. Who Should Attend: QC analysts performing KF titration on battery raw materials, electrolytes, and separators.  R&D scientists searching for improvements on their research projects.  Anyone from the battery market wanting to learn about how important this analysis is for their materials and products.  Brought to you by: Speakers: Dr. Roman Neufeld Sr. Research Scientist Honeywell Eduardo Simões Product Specialist Metrohm USA Ann Thayer Contributing Editor C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
In this webinar we will show you how Unchained technologies can be paired together to form an Unchained "Ecosystem" and how this enables an efficient workflow for Drug Product Formulation development which leverages a high throughput approach, low volume microfluidics, and automation.    Further, we will illustrate efforts to integrate with robotic automation on the front end of this workflow and automation of the "data analysis lake" on the back end. You will appreciate how IGM is leading the way to efficiently identify stabilizing formulations and rapidly identify stable monoclonal antibody (mAb) Drug Products.    Key Learning Objectives: Develop a technical understanding of Unagi, Honeybun, and Stunner functionality. Appreciate how the technologies establish a functional Unchained Ecosystem for biologics development. Understand how to utilize an integrated volume-sparing, high throughput, automated workflow without the need for costly and high footprint utility demanding robotic workstations. Who Should Attend: Drug Product Development leaders seeking low volume, automated, and high throughput strategies for accelerating formulation screening. Development scientists in need of automated UF/DF, coupled to rapid analytical assessment of viscosity, protein concentration, aggregation, and colloidal stability. Brought to you by:             Speakers:   Christopher Mensch Director of Drug Product Development & Research, IGM Biosciences       Sameer Sachdeva, PhD Sr. Scientist of Drug Product Development, IGM Biosciences       Kevin Lance, PhD Director, Marketing, Unchained Labs       Ann Thayer Contributing Editor, C&EN Media Group        
ACS Webinars Hub Placeholder Image.png
Labels (2)
X-ray Absorption Spectroscopy (XAS) is a powerful and versatile technique that fits into the larger landscape of material characterization techniques by providing unique, element-specific insights into the local atomic structure, electronic properties, and bonding interactions of materials. It complements and enhances the information obtained from other characterization methods, contributing to a more comprehensive understanding of materials.     In this session, we will discuss the utility of XAS and how newly developed lab-scale instrumentation enables its practical use as an everyday tool for materials characterization. Come see real world applications of laboratory XAS.    Key Learning Objectives: Introduction to X-ray Absorption Spectroscopy and its unique capabilities for materials characterization. Detailed look into example applications of laboratory XAS.  Overview of new lab-scale XAS instrumentation. Understanding the process of conducting a laboratory XAS measurement, including a real-time measurement demonstration.  Who Should Attend: Research Scientists from Universities or Industries that routinely perform materials characterization. Materials Characterization Lab Managers and Users interested in understanding new techniques. Those interested in element-specific, non-destructive material analysis. Brought to you by: Speakers: Dr. Devon Mortensen CEO, easyXAFS Dr. William Holden CTO, easyXAFS Dr. Zachary Lebens-Higgins Testing and R&D Manager, easyXAFS Catherine Dold Health & Environment Writer, C&EN Media Group
%7Bf5943144-ae31-4e7f-b5dd-2921be25a0a4%7D_C_EN_webinar_graphic
Labels (2)
With the rising clinical and commercial successes of AAV-based gene therapies, there is an ever-growing demand for robust, platform analytical technologies that can help ensure better product quality, safety, and efficacy. Size exclusion chromatography (SEC) and Field Flow Fractionation (FFF), coupled with multi-angle light scattering technologies (MALS), are rapidly emerging as transformative technologies for rapid and accurate characterization of AAV samples. Critical Quality Attributes (CQAs) such as capsid titer, genome titer, empty/full, % aggregation and purity of various AAV serotypes can all be obtained in a single measurement. This multi-attribute approach dramatically reduces operational costs and reduces drug development timelines.     Key Learning Objectives: See how SEC-MALS compares to orthogonal techniques (ddPCR, Capsid ELISA’s, and AUC) for the characterization of AAV during various downstream steps   Understand how light scattering can be used as a rapid screening tool when working with multiple AAV serotypes  Appreciate the value of FFF-MALS for accurate, AAV aggregation analysis   Who Should Attend: Academic researchers involved in biophysical studies  Academic researchers involved in gene therapy studies  Gene Therapy - Discovery  Gene Therapy - Development Gene Therapy – QC Government researchers involved in gene therapy research Brought to you by:   Speakers: Steven Milian, M.S. Sr. Staff Scientist, Research & Development Dept. of Patheon (by Thermo Fisher Scientific) Viral Vector Services Gennarino Del Bagno, B.S. Lead Scientist, Research & Development Dept. of Patheon (by Thermo Fisher Scientific) Viral Vector Services Melissa O'Meara Forensic Science Consultant, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Thursday, October 19, 2023
Glycosylation plays a crucial role in determining the pharmacological properties of biotherapeutics. The molecular heterogeneity of glycosylated biotherapeutics makes it difficult to provide thorough characterization of intact glycoproteins by mass spectrometry. Current methods for analyzing biotherapeutics only measure fragments of the compound or rely on partial digestion of the glycans to reduce sample complexity. These limitations pose important risks and challenges for biotechnology companies that need to report human-compatible and consistent glycosylation, critical for drug safety and efficacy.     We will present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. In addition, we highlight the application of charge detection native mass spectrometry (Direct Mass Technology mode) towards the elucidation of masses and aggregation of heterogeneous glycosylated biotherapeutics.    Key Learning Objectives: How to elucidate masses from heterogeneous glycosylated biotheraputics  Learn how proton transfer charge reduction (PTCR) can simplify complex protein mixtures  Learn when to use PTCR based methods compared to Direct Mass Technology mode for analysis of biotherapeutics  Who Should Attend: Laboratory Managers  Biopharmaceutical Researchers  Protein Scientists  Brought to you by: Speakers: Wendy Sandoval Director, Translational Mass Spectrometry, Genentech Ann Thayer Contributing Editor, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)